Scandinavian ChemoTech signs commissioned research agreement with Kalqyl
Scandinavian ChemoTech AB has entered into an agreement with Kalqyl AB to carry out an initial analysis of the Company.
The purpose of the analysis is to increase the stock market's knowledge of ChemoTech and to make the Company's value-driving factors visible in the short and the long term.
After publication, the analysis will be disseminated on Kalqyl's Twitter channels and also via Nordnet, Avanza, Di.se, Eikon, Bloomberg and more.
The analysis is expected to be published in July 2022.
About Kalqyl
Kalqyl is run by analysts Oliver Hamrin, Peter Westberg and Pontus Fredriksson, who are behind the Twitter accounts "Professor Kalkyl", "Matematikern" and "Carl-Philip Silwersköld". Through the Kalqyl service, listed companies are offered assignment analyses in connection with a new share issue, a stock exchange listing or just to increase awareness of the Company among private investors. Kalqyl is a wholly owned subsidiary of Spotlight Group and was acquired in August 2021.
For further information please contact: Mohan Frick, CEO
+46 (0)10-218 93 00
info@chemotech.se
Certified Adviser: Erik Penser Bank, Tel: +46 8 463 80 00, E-mail: certifiedadviser@penser.se
Scandinavian ChemoTech AB (publ)
ChemoTech is a Swedish medical technology company based in Lund that has developed a patented technology platform to offer cancer patients access to a new treatment alternative, Tumour Specific Electroporation (TSE™), available for treatment of both humans and animals. There are a large number of cancer patients whose tumours for various reasons cannot be treated by conventional methods but where TSE can be a solution. Therefore, the company continuously evaluates new opportunities and areas of application for the technology. ChemoTech's shares (CMOTEC B) are listed on Nasdaq First North Growth Market in Stockholm and Erik Penser Bank is the company's Certified Adviser. Read more at: www.chemotech.se.
